Troponin T and β-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy

Cardiovascular Research

Volumn 77, Issue 4, 2008, Pages 687-694

  Revera, Miriam ^a   Van Der Merwe, Lize ^b   Heradien, Marshall ^c   Goosen, Althea ^c   Corfield, Valerie A ^d   Brink, Paul A ^c   Moolman Smook, Johanna C ^d,e  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

myosin; Contractile function; Hypertrophic cardiomyopathy; Mutation; Troponin T

Indexed keywords

CALCIUM; MYOSIN HEAVY CHAIN BETA; TROPONIN T;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DOPPLER ECHOCARDIOGRAPHY; FEMALE; GENE MUTATION; GENOTYPE; HEART FUNCTION; HETEROZYGOTE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHY; IN VITRO STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; THIN FILAMENT;

ADENOSINE TRIPHOSPHATE; ADULT; ANIMALS; CALCIUM SIGNALING; CARDIAC MYOSINS; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GENOTYPE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUTATION; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOSIN HEAVY CHAINS; PHENOTYPE; TROPONIN T; VENTRICULAR FUNCTION, LEFT;

EID: 39749164101     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm075     Document Type: Article

References (33)

1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-789.
2. Van Driest SL, Maron BJ, Ackerman MJ. From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy. Heart 2004;90:7-8.
3. Harada K, Potter JD. Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction. J Biol Chem 2004;279:14488-14495.
4. Wang Y, Xu Y, Kerrick WG, Wang Y, Guzman G, Diaz-Perez Z et al. Prolonged Ca2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations. J Mol Biol 2006;361:286-299.
5. Tardiff JC. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005;10:237-248.
6. Ertz-Berger BR, He H, Dowell C, Factor SM, Haim TE, Nunez S et al. Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice. Proc Natl Acad Sci USA 2005;102:18219-18224.
7. Van Driest SL, Jaeger MA, Ommen SR, Will ML, Gersh BJ, Tajik AJ et al. Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:602-610.
8. Woo A, Rakowski H, Liew JC, Zhao MS, Liew CC, Parker TG et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis. Heart 2003;89:1179- 1185.
9. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986;55:575-581.
10. Moolman-Smook JC, De Lange WJ, Bruwer EC, Brink PA, Corfield VA. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. Am J Hum Genet 1999;65:1308-1320.
11. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
12. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
13. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
14. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet 2006;2:e132.
15. Maass AH, Ikeda K, Oberdorf-Maass S, Maier SK, Leinwand LA. Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T. Circulation 2004;110:2102- 2109.
16. Knollmann BC, Blatt SA, Horton K, de Freitas F, Miller T, Bell M et al. Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79 N) mutation linked to familial hypertrophic cardiomyopathy. J Biol Chem 2001;276:10039-10048.
17. Oberst L, Zhao G, Park JT, Brugada R, Michael LH, Entman ML et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest 1998;102:1498-1505.
18. Ono K, Masuyama T, Yamamoto K, Doi R, Sakata Y, Nishikawa N et al. Echo doppler assessment of left ventricular function in rats with hypertensive hypertrophy. J Am Soc Echocardiogr 2002;15:109-117.
19. Sebag IA, Handschumacher MD, Ichinose F, Morgan JG, Hataishi R, Rodrigues AC et al. Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 2005;111:2611-2616.
20. Schaper WK, Lewi P, Jageneau AH. The determinants of the rate of change of the left ventricular pressure (dP/dt). Arch Kreislaufforsch 1965;46:27-41.
21. Lutucuta S, Tsybouleva N, Ishiyama M, Defreitas G, Wei L, Carabello B et al. Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. J Am Coll Cardiol 2004;44:2221-2230.
22. Miller T, Szczesna D, Housmans PR, Zhao J, de Freitas F, Gomes AV et al. Abnormal contractile function in transgenic mice expressing a familial hypertrophic cardiomyopathy-linked troponin T (I79 N) mutation. J Biol Chem 2001;276:3743-3755.
23. Senzaki H, Isoda T, Paolocci N, Ekelund U, Hare JM, Kass DA. Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. Circulation 2000;101:1040-1048.
24. Revera M, Van Der ML, Heradien M, Goosen A, Corfield VA, Brink PA et al. Long-term follow-up of R403W(MYH7) and R92W(TNNT2) HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression. Cardiovasc J S Afr 2007;18:146-153.
25. Yamashita H, Tyska MJ, Warshaw DM, Lowey S, Trybus KM. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. J Biol Chem 2000;275:28045-28052.
26. Keller DI, Coirault C, Rau T, Cheav T, Weyand M, Amann K et al. Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol 2004;36:355-362.
27. Tian R, Christe ME, Spindler M, Hopkins JC, Halow JM, Camacho SA et al. Role of MgADP in the development of diastolic dysfunction in the intact beating rat heart. J Clin Invest 1997;99:745-751.
28. Kagaya Y, Weinberg EO, Ito N, Mochizuki T, Barry WH, Lorell BH. Glycolytic inhibition: effects on diastolic relaxation and intracellular calcium handling in hypertrophied rat ventricular myocytes. J Clin Invest 1995;95:2766-2776.
29. Poggesi C, Tesi C, Stehle R. Sarcomeric determinants of striated muscle relaxation kinetics. Pflugers Arch 2005;449:505-517.
30. Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L, Warshaw DM. R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res Cell Motil 2000;21:609-620.
31. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:317-324.
32. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999;34:1813-1822.
33. Kosutic J, Zamurovic D. High-dose beta-blocker hypertrophic cardiomyopathy therapy in a patient with Friedreich ataxia. Pediatr Cardiol 2005;26:727-730.